4858 Results for "acquisition"

Exscientia enhances AI with acquisition of Allcyte

—Exscientia enhances AI with acquisition of Allcyte “ ” Exscientia, a British provider of artificial intelligence for drug discovery with its own drug pipeline, will acquire Allcyte, an Austrian developer of AI applications for precision medicine, for about $60 million. Exscientia says the purchase will add the ability to perform high-content evaluation of individual patient biology in primary tumor tissues rather than in artificial cell lines or animal models, allowing integrated drug discovery and patient selection.

by Rick Mullin | June 20, 2021

GSK Scores Proteomics In Cellzome Acquisition

—GSK Scores Proteomics In Cellzome Acquisition “” GlaxoSmithKline has agreed to acquire the shares it does not currently own in Cell­zome to access the latter’s proteomics platform for drug development. GSK currently owns just less than 20% of Cellzome through previous drug development collaborations.

by Rick Mullin | May 21, 2012

Akzo Sees Synergies In ICI Acquisition

—Akzo Sees Synergies In ICI Acquisition “” Akzo Nobel managers estimate that operating cost savings and other synergies from their acquisition of ICI's paints business will total nearly $3.5 billion, after implementation costs. In a shareholder circular, the company confirmed that it intends to find a new owner for ICI's specialty starches business, while retaining ICI's specialty polymers business.

October 08, 2007

Emerging drug firms reap investments

But that amount is dwarfed by the $300 billion that came from the up-front fees paid in global licensing deals and acquisitions during the same period. In 2015, acquisitions of emerging firms reached a 10-year peak of $62.2 billion compared with the low point of $14.6 billion in postrecession 2009.

by Ann M. Thayer | June 09, 2016

Moody’s cautions European chemical firms over deals

—Moody’s cautions European chemical firms over deals “” Many European chemical makers have had their fill of acquisitions, according to Moody’s. The credit ratings agency says that after a spate of large acquisitions, a few chemical makers won’t be able to make any further acquisitions in the next 12 to 18 months without risking a credit downgrade. But companies may be tempted to make acquisitions anyway, according to Francois Lauras, Moody’s vice president and senior credit officer. “Pressure to continue acquisitions to boost future revenue and earnings growth is intense as firms struggle to grow organically post-2008,” he says. Large chemical companies that made big deals recently include Solvay, Evonik Industries, and Lanxess. However, Moody’s says a handful of other firms, including AkzoNobel, Covestro, and Arkema, have the balance sheets to make acquisitions without hurting their credit. /articles/95/i7/Moodys-cautions-European-chemical-firms.html 20170213 Concentrates 95 7 /magazine/95/09507.html Moody’s cautions European chemical firms over deals finance, mergers & acquisitions, Europe, deals con bus Alexander H.

by Alexander H. Tullo | February 13, 2017

Pharmaceutical dealmaking hit a peak in 2018

—Pharmaceutical dealmaking hit a peak in 2018 “Changes at drug majors include OTC division sales to focus on innovation” Mergers and acquisitions in the drug industry last year brought one particularly high price tag: Takeda Pharmaceutical’s $59.0 billion acquisition of Shire. But just as interesting was how 2018’s deal-making reflected a transformation underway among the largest companies, according to new reports by the investment firms HBM Partners and Kurmann Partners.

by Rick Mullin | February 06, 2019

Pfizer Acquisition Targets Protein Misfolding

—Pfizer Acquisition Targets Protein Misfolding “” Pfizer will purchase privately held FoldRx Pharmaceuticals, of Cambridge, Mass., for an undisclosed upfront fee and future milestone payments. FoldRx develops small-molecule drugs to treat chronic diseases resulting from protein misfolding and aggregation.

by Ann M. Thayer | September 06, 2010

Bayer clears path to clinch Monsanto acquisition by divesting more to BASF

—Bayer clears path to clinch Monsanto acquisition by divesting more to BASF “BASF will buy agrochemical and seed businesses for $2 billion” Bayer has agreed to sell a second tranche of agrochemical and seed businesses to BASF for $2 billion. The move should enable Bayer to satisfy European Union competition rules and complete its $63.5 billion deal to acquire Monsanto—first announced in September 2016—by July.

by Alex Scott | May 06, 2018

Emerging drug firms reap investments

Corteva continues push into biologicals with Stoller acquisition

—Corteva continues push into biologicals with Stoller acquisition “” Corteva Agriscience has agreed to buy the crop biologicals company Stoller Group for $1.2 billion. Stoller makes microbial and other products that can improve a plant’s ability to absorb nutrients or tolerate stressful conditions.

by Matt Blois | December 15, 2022